Based in Billerica of Massachusetts, RainDance provides droplet technology, which can be used for research in areas such as non-invasive liquid biopsy.
With applications in life science research and clinical research, the firm’s foundational intellectual property portfolio and product lines feature a range of biological reactions in droplets.
The company produces ultra-sensitive genomic tools, including RainDrop digital PCR, ThunderStorm, and ThunderBolts next-generation sequencing enrichment products.
Developed for research institutions and laboratories, the tools will allow to detect genetic variations in cancer, as well as inherited and infectious diseases.
The deal is expected to complete in the first quarter of this year.
Bio-Rad president and CEO Norman Schwartz said: “The company’s droplet-based solutions will extend our reach into next generation sequencing applications and strengthen our position in the area of Droplet Digital PCR.
“We look forward to expanding our offering to provide life science and clinical diagnostics customers with solutions for a wide range of nucleic acid detection applications.”
Bio-Rad is engaged in the development, manufacturing and marketing of products and solutions for the life science research and clinical diagnostic markets.
The firm’s products will be used by university and research institutions, hospitals, public health and commercial laboratories. It also provides solutions to the biotechnology, pharmaceutical and food safety industries.
